Verrica Pharmaceuticals Inc. Common Stock (VRCA)

Price$5.87

Value ScoreC

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)9.09%

Price vs S&P 500 (4W)-24.08%

VGM Score65.97

Market Capitalization$99.47M

All Metrics

Book Value / Share (Quarterly)$0.93

P/TBV (Annual)3.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)57.94%

Cash Flow / Share (Quarterly)$-0.82

Price vs S&P 500 (YTD)-41.71%

Gross Margin (TTM)89.52%

Net Profit Margin (TTM)-47.97%

EPS (TTM)$-1.03

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-1.03

EPS (Annual)$-1.68

ROI (Annual)-69.35%

Gross Margin (Annual)90.33%

Net Profit Margin (5Y Avg)-586.69%

Cash / Share (Quarterly)$1.20

Revenue Growth QoQ (YoY)46.06%

ROA (Last FY)-37.95%

Revenue Growth TTM (YoY)417.63%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-141.89%

Operating Margin (TTM)-41.18%

Cash Flow / Share (Annual)$-1.03

P/B Ratio6.20x

P/B Ratio (Quarterly)5.66x

Net Income / Employee (Annual)$-235,300

EV / Revenue (TTM)2.15x

Net Interest Coverage (TTM)-3.29x

ROA (TTM)-42.97%

EPS Incl Extra (Annual)$-1.68

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)1.84x

3-Month Avg Trading Volume0.11M

52-Week Price Return7.02%

Revenue / Employee (TTM)$489,000

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)2.80x

Asset Turnover (Annual)0.75x

52-Week High$9.82

Operating Margin (5Y Avg)-540.49%

EPS Excl Extra (Annual)$-1.68

CapEx CAGR (5Y)-47.55%

Tangible BV CAGR (5Y)36.44%

26-Week Price Return22.67%

Quick Ratio (Annual)2.28x

13-Week Price Return7.82%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)2.10x

Enterprise Value$79.81M

Asset Turnover (TTM)0.90x

Book Value / Share Growth (5Y)-10.58%

Revenue / Employee (Annual)$468,100

Pretax Margin (Annual)-50.27%

Cash / Share (Annual)$1.75

3-Month Return Std Dev90.17%

Net Income / Employee (TTM)$-234,600

ROE (Last FY)-72.29%

Net Interest Coverage (Annual)-1.71x

EPS Basic Excl Extra (Annual)$-1.68

Receivables Turnover (TTM)5.58x

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-1.03

ROI (TTM)-83.00%

P/S Ratio (TTM)2.68x

Pretax Margin (5Y Avg)-586.69%

Revenue / Share (Annual)$3.34

Tangible BV / Share (Annual)$0.97

Price vs S&P 500 (52W)-21.13%

Year-to-Date Return-30.32%

5-Day Price Return-4.46%

EPS Normalized (Annual)$-1.68

ROA (5Y Avg)-72.01%

Net Profit Margin (Annual)-50.27%

Month-to-Date Return0.52%

Cash Flow / Share (TTM)$-1.08

EBITD / Share (Annual)$-1.24

Operating Margin (Annual)-38.56%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-68.97%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)3.76x

P/B Ratio (Annual)3.19x

Inventory Turnover (TTM)1.76x

Pretax Margin (TTM)-47.97%

Book Value / Share (Annual)$1.44

Price vs S&P 500 (13W)-2.84%

Beta1.52x

Revenue / Share (TTM)$1.74

ROE (TTM)-87.04%

52-Week Low$3.28

vGradeC

gGradeA

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.41est. -0.39

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VRCAVerrica Pharmaceuticals Inc. Common Stock	C	A	C	$5.87
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Verrica Pharmaceuticals is a dermatology therapeutics company developing novel treatments for contagious viral skin diseases. Its lead product candidate, VP-102, targets molluscum contagiosum and common warts, addressing significant market opportunities in pediatric and adult populations.